FindTrial
Sign In

Comparison of GomutraTriphala Vati and Tab Atorvastatin in Sthaulya(Obesity and Hyperlipidemia)

A Randomized controlled clinical trial to evaluvate the efficacy between GomutraTriphala Vati and Atorvastatin in the management of Medovruddhi in Sthaulya with special reference to Hyperlipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032449
Enrollment
62
Registered
2021-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E660- Obesity due to excess calories

Interventions

Intervention1: GomutraTriphala Vati: Group A will be treated with GomutraTriphala vati containing Gomutra,Triphala. GomutraTriphala Vati will be given orally in the dose of 500 mg twice a day before m

Sponsors

PDEAs College of Ayurved and Research Centre NigdiPune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1Patients suffering from Medovruddhijanit symptoms in Sthaulya. 2Patients who are having two or more following symptoms will be included for the study 1 SHWASADHIKYA 2 NIDRADHIKYA 3 AAYAS AKSHAMATA 4 JADDYA 5 BALAHEENATA 6 ATI KSHUDHA 7 ATI TRUSHNA 3Age group having 25 to 65 years age,irrespective of any gender,socio economic status and religion. 4B.M.I 25.0 to 35 kg/m2. 5Patient having Serum Total Cholesterol Level more than 200mg/dl 6Patient having Serum Triglyceride Level more than 150mg/dl

Exclusion criteria

Exclusion criteria: 1Pregnant and Lactating women. 2Known cases of Uncontrolled Diabetes Mellitus with Its Complications. 3Known cases of Major systemic diseases such as TB,AIDS,IHD,CA,Renal and Cerebral diseases. 4Known cases of Acute complications like Coronary Heart Disease,Hepatitis. 5High risk (above 65 yrs age,known cases of HTN,DM,COPD) 6Comorbid patients Suspected for Covid-19. Suspected Covid-19 patients having symptoms as per ICMR guidelines.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of GomutraTriphala Vati 500 mg twice a day before meal with lukewarm water with Tab.Atorvastatin 10 mg once a day at night with water in Medovruddhi in Sthaulya with special reference to Hyperlipidemia within 60 daysTimepoint: 60 days with follow up on 15th,30th,45th,60th day—

Secondary

MeasureTime frame
1.To compare and study the efficacy of GomutraTriphala Vati. 2.To compare and study the efficacy of Tab.Atorvastatin 3.To study the adverse effects if any.Timepoint: 60 days with follow up on 15th,30th,45th,60th day—

Countries

India

Contacts

Public ContactDr Gargi Sanjay Limaye

PDEAS College of Ayurved and Research Centre,Nigdi ,Pune

medhamaheshjoshi@gmail.com9881465798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026